Brief: Ascentage Pharma Says Olverembatinib (HQP1351) Recommended For Breakthrough Therapy Designation
24/03/2021 11:38
March 24 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ASCENTAGE PHARMA'S FIRST THIRD-GENERATION BCR-ABL
INHIBITOR IN
CHINA OLVEREMBATINIB (HQP1351) RECOMMENDED FOR BREAKTHROUGH
THERAPY DESIGNATION
* ASCENTAGE PHARMA'S FIRST THIRD-GENERATION BCR-ABL
INHIBITOR IN
CHINA OLVEREMBATINIB (HQP1351) RECOMMENDED FOR BREAKTHROUGH
THERAPY DESIGNATION
Source text for Eikon: ID:nPn5Gd55Na
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up